Skip to main navigation
Skip to search
Skip to main content
University of Limerick Home
Home
Profiles
Research units
Research output
Prizes
Activities
Press/Media
Student theses
Search by expertise, name or affiliation
Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells
Francesco Caiazza
, Alyson Murray
, Stephen F. Madden
, Naoise C. Synnott
,
Elizabeth J. Ryan
, Norma O'Donovan
, John Crown
, Michael J. Duffy
University College Dublin
Royal College of Surgeons in Ireland
Dublin City University
Research output
:
Contribution to journal
›
Article
›
peer-review
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Preclinical evaluation of the AR inhibitor enzalutamide in triple-negative breast cancer cells'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Immunology and Microbiology
Breast Cancer Cell Line
50%
Cancer Cell
100%
Cell Growth
100%
Cell Invasion
100%
Cell Line
50%
Cell Migration
100%
down Regulation
50%
Gene Expression Assay
50%
IC50
50%
Overall Survival
50%
Transcription Factors
50%
Biochemistry, Genetics and Molecular Biology
Androgen Receptor
100%
AP-1 Transcription Factor
9%
Cancer Cell
100%
Cell Growth
18%
Cell Invasion
18%
Cell Migration
18%
down Regulation
9%
Enzalutamide
100%
Gene Expression Profiling
9%
IC50
9%
Overall Survival
9%
Pharmacology, Toxicology and Pharmaceutical Science
Androgen
9%
Androgen Receptor
100%
Antiandrogen
18%
Breast Cancer
27%
Enzalutamide
100%
Flutamide
9%
IC50
9%
Overall Survival
9%
Transcription Factors
9%
Triple Negative Breast Cancer
100%
Neuroscience
Androgen
9%
Androgen Receptor
100%
Antiandrogen
18%
AP-1 Transcription Factor
9%
Cell Growth
18%
Cell Invasion
18%
Cell Line
18%
Cell Migration
18%
Enzalutamide
100%
Flutamide
9%
Gene Expression
9%
Receptor Expression
9%